Intercept Pharmaceuticals, Inc. (ICPT) Bundle
A Brief History of Intercept Pharmaceuticals, Inc. (ICPT)
Foundation and Early Years
Intercept Pharmaceuticals, Inc. was founded in 2002, focusing on the development of novel therapeutics to treat liver diseases. The company was established by a group of scientists and entrepreneurs, including Mark Pruzanski, who has served as the President and CEO since its inception.
Initial Public Offering (IPO)
In 2013, Intercept went public with an IPO on the NASDAQ, raising approximately $109 million. The opening price was set at $18 per share, with an initial valuation of about $500 million.
Development of Obeticholic Acid
Intercept's lead product candidate, obeticholic acid (OCA), is a modified bile acid that activates the farnesoid X receptor (FXR). In 2016, OCA received breakthrough therapy designation from the FDA for the treatment of primary biliary cholangitis (PBC).
Regulatory Approvals
In May 2016, OCA was approved by the FDA for PBC, marking a significant milestone for the company. The FDA approved the drug with a list price of approximately $70,000 per year.
Financial Performance
In 2021, Intercept reported revenues of $258 million primarily from the sales of OCA. The net income for the year was reported as -$200 million due to increased research and development expenses and operational costs.
Market Capitalization and Stock Performance
As of October 2023, Intercept's market capitalization stands at approximately $1.4 billion. The stock price has experienced significant fluctuations, peaking at around $120 per share in early 2021 before declining to around $20 per share in late 2023.
Table of Financial Data
| Year | Revenue ($ million) | Net Income ($ million) | Stock Price ($) | Market Capitalization ($ billion) |
|---|---|---|---|---|
| 2016 | 10 | -28 | 25 | 0.5 |
| 2017 | 39 | -78 | 22 | 0.9 |
| 2018 | 71 | -110 | 60 | 2.8 |
| 2019 | 146 | -166 | 45 | 1.5 |
| 2020 | 209 | -260 | 40 | 1.1 |
| 2021 | 258 | -200 | 62 | 1.6 |
| 2022 | 235 | -220 | 30 | 0.8 |
| 2023 | 150 | -180 | 20 | 1.4 |
Research and Development
Intercept has invested heavily in research and development, with R&D expenses exceeding $250 million annually in recent years. The company is conducting multiple clinical trials to explore OCA's efficacy in treating conditions such as non-alcoholic steatohepatitis (NASH) and other liver diseases.
Collaborations and Partnerships
In 2022, Intercept partnered with universities and research institutions, focusing on liver disease research. Collaborations included a strategic alliance with Gilead Sciences to explore combination therapies.
Recent Developments
In late 2023, Intercept announced the initiation of multiple phase 3 clinical trials for OCA, targeting NASH with a focus on liver fibrosis. The company's ongoing commitment to innovation has positioned it as a key player in the liver disease therapeutic market.
A Who Owns Intercept Pharmaceuticals, Inc. (ICPT)
Shareholder Composition
The ownership structure of Intercept Pharmaceuticals, Inc. (ICPT) consists of both institutional and retail investors. As of the most recent filings, the following table outlines the major shareholders of ICPT.
| Type of Owner | Owner Name | Ownership Percentage | Shares Owned |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 10.4% | 2,163,023 |
| Institutional Investor | Vanguard Group, Inc. | 7.2% | 1,496,172 |
| Institutional Investor | State Street Corporation | 5.9% | 1,233,930 |
| Institutional Investor | GVF Capital Management, LLC | 5.3% | 1,094,638 |
| Retail Investor | Individual Shareholders | 71.2% | 14,803,978 |
Insider Ownership
As of the latest data, insider ownership at Intercept Pharmaceuticals is represented as follows:
| Name | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Mark Pruzanski | President & CEO | 420,000 | 2.0% |
| David Shapiro | CFO | 250,000 | 1.2% |
| Dr. S. William Stetson | Chief Medical Officer | 150,000 | 0.7% |
| Jason C. Pomerantz | SVP, Corporate Development | 100,000 | 0.5% |
Recent Market Performance
Intercept Pharmaceuticals, Inc. has shown significant fluctuations in its stock performance. The following table summarizes recent financial metrics:
| Metric | Value |
|---|---|
| Current Stock Price (as of October 2023) | $14.25 |
| Market Capitalization | $487 million |
| 52-Week High | $20.40 |
| 52-Week Low | $8.10 |
| Price-to-Earnings Ratio (P/E) | N/A |
Recent Financing Activities
Intercept Pharmaceuticals has recently engaged in financing activities that may affect ownership structure, including:
- Public Offering: Raised $50 million in August 2023.
- Debt Issuance: Issued $35 million in convertible debt.
Conclusion of Ownership Trends
The ownership trends of Intercept Pharmaceuticals indicate that institutional investors hold a significant portion of shares, while a large percentage remains with retail investors. Continuous monitoring of shareholder composition will be crucial for understanding future company dynamics.
Intercept Pharmaceuticals, Inc. (ICPT) Mission Statement
Core Mission Statement
The mission of Intercept Pharmaceuticals, Inc. is to develop and commercialize innovative therapeutics to treat liver diseases and to be the leader in this field. The company is focused on addressing significant unmet medical needs despite the complexities of liver disease management.
Company Vision
Intercept aims to pioneer new therapies that provide meaningful benefits to patients suffering from liver diseases. Their vision includes a commitment to scientific excellence and patient-centric approaches in drug development.
Strategic Goals
- To advance the development of novel therapeutics that address liver diseases.
- To maintain a robust clinical pipeline for addressing high unmet medical needs.
- To foster partnerships and collaborations that enhance research and development efforts.
- To uphold high standards of regulatory compliance throughout the clinical development process.
- To achieve commercialization of effective therapies that improve patient outcomes and quality of life.
Financial Overview
As of the most recent fiscal report, Intercept Pharmaceuticals reported the following financial figures:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue (2022) | $66.2 million |
| Net Loss (2022) | $(140.5) million |
| Total Assets (2023) | $277.3 million |
| Total Liabilities (2023) | $135.9 million |
| Cash and Cash Equivalents (2023) | $109.5 million |
| Market Capitalization (as of Oct 2023) | $410 million |
| Cash Burn Rate (Q2 2023) | $(30.1) million |
Key Products and Pipeline
Intercept Pharmaceuticals is known for its flagship product, Ocaliva (obeticholic acid), which is utilized in the treatment of primary biliary cholangitis (PBC). The current product pipeline includes:
| Product | Indication | Development Stage |
|---|---|---|
| Ocaliva | Primary Biliary Cholangitis | Commercialized |
| IBAT Inhibitor | Nonalcoholic Steatohepatitis (NASH) | Phase 3 |
| Other Investigational Therapies | Various liver conditions | Preclinical |
Commitment to Research
Intercept is committed to ongoing research and development, allocating over $100 million annually towards this initiative. The company believes in continuous improvement and adaptation of their therapeutic approaches based on the latest scientific discoveries.
Community Engagement
Intercept actively engages with patient advocacy groups and healthcare professionals to ensure that their developments align closely with the needs of patients. They aim to enhance awareness about liver diseases through educational initiatives and support programs.
How Intercept Pharmaceuticals, Inc. (ICPT) Works
Company Overview
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat liver diseases. The company is headquartered in New York City and was founded in 2002.
Core Product Offering
The primary product of Intercept Pharmaceuticals is Ocaliva (obeticholic acid), which received FDA approval in May 2016. Ocaliva is indicated for the treatment of primary biliary cholangitis (PBC) in adults.
| Product | Indication | FDA Approval Date | Sales (2022) |
|---|---|---|---|
| Ocaliva | Primary Biliary Cholangitis (PBC) | May 2016 | $235 million |
Financial Performance
In the fiscal year 2022, Intercept Pharmaceuticals reported total revenues of approximately $259 million, with a significant portion attributed to sales of Ocaliva.
| Year | Total Revenue | Net Loss | Cash and Cash Equivalents |
|---|---|---|---|
| 2022 | $259 million | ($214 million) | $183 million |
| 2021 | $304 million | ($265 million) | $246 million |
Research and Development Focus
Intercept Pharmaceuticals invests heavily in research and development to expand its portfolio. As of 2022, the company had several clinical trials focused on various liver diseases, including non-alcoholic steatohepatitis (NASH).
Market Position
Intercept operates in the competitive landscape of liver disease therapeutics. Key competitors include:
- Gilead Sciences, Inc.
- Bristol-Myers Squibb Company
- Galmed Pharmaceuticals Ltd.
Stock Performance
As of October 2023, the stock price of Intercept Pharmaceuticals (ICPT) is approximately $20.00. The market capitalization stands at around $653 million.
| Date | Stock Price ($) | Market Capitalization ($ million) | P/E Ratio |
|---|---|---|---|
| October 2023 | $20.00 | $653 million | N/A |
Management Team
The leadership team of Intercept Pharmaceuticals consists of experienced professionals in the biopharmaceutical industry. Key members include:
- Mark Pruzanski - President and CEO
- Sander van Deventer - Chief Financial Officer
- David Shapiro - Chief Medical Officer
Partnerships and Collaborations
To enhance its capabilities, Intercept Pharmaceuticals engages in partnerships with other organizations. Notable collaborations include:
- Partnership with Genfit for NASH-related therapies.
- Collaboration with AbbVie to explore combination therapies.
Regulatory Environment
As a biopharmaceutical company, Intercept Pharmaceuticals operates under stringent regulations by the FDA and other global health agencies. Compliance with Good Manufacturing Practices (GMP) and conducting rigorous clinical trials are essential components of the regulatory landscape.
Conclusion of Operational Capacity
In summary, Intercept Pharmaceuticals positions itself as a key player in the liver disease therapeutic market, focusing on innovation and strategic partnerships to drive growth and expand its product pipeline.
How Intercept Pharmaceuticals, Inc. (ICPT) Makes Money
Product Revenue
Product Revenue
Intercept Pharmaceuticals generates revenue primarily through its flagship product, Ocaliva (obeticholic acid). In 2022, the total revenue from Ocaliva sales reached approximately $220 million, reflecting a year-over-year increase of 16%.
| Year | Ocaliva Revenue (in millions) | Year-over-Year Growth (%) |
|---|---|---|
| 2020 | $187 | 14% |
| 2021 | $190 | 1.6% |
| 2022 | $220 | 15.8% |
Geographical Sales Distribution
The revenue from Ocaliva varies significantly by region. In 2022, the revenue breakdown was as follows:
| Region | Revenue (in millions) | Percentage of Total Revenue (%) |
|---|---|---|
| United States | $150 | 68% |
| Europe | $70 | 32% |
Research and Development (R&D) Collaborations
Intercept also generates income through R&D collaborations. In 2022, the company reported collaboration revenue of $30 million attributed to partnerships with other pharmaceutical companies.
| Year | Collaboration Revenue (in millions) |
|---|---|
| 2020 | $25 |
| 2021 | $20 |
| 2022 | $30 |
Future Growth Prospects
Intercept Pharmaceuticals is focusing on expanding its product pipeline, including potential new indications for Ocaliva and other investigational therapies. The company has estimated that if successful, new product launches could increase total revenue by up to $300 million by 2025.
| Pipeline Product | Expected Launch Year | Projected Revenue (in millions) |
|---|---|---|
| Ocaliva for NASH | 2024 | $200 |
| Other Investigational Therapies | 2025 | $100 |
Financial Performance Metrics
As of Q3 2023, Intercept Pharmaceuticals reported the following financial metrics:
| Metric | Value |
|---|---|
| Total Assets (as of 2023) | $500 million |
| Total Liabilities (as of 2023) | $350 million |
| Market Capitalization (as of 2023) | $700 million |
Operating Expenses
The company’s total operating expenses in 2022 were approximately $300 million, with specific allocations as follows:
| Expense Category | Amount (in millions) |
|---|---|
| R&D | $180 |
| Sales and Marketing | $100 |
| General and Administrative | $20 |
Intercept Pharmaceuticals, Inc. (ICPT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support